Nuformix (LON:NFX) Stock Price Down 12.7% – What’s Next?

Shares of Nuformix plc (LON:NFX) dropped 12.7% during trading on Tuesday . The stock traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 16,142,512 shares traded hands during trading, a decline of 74% from the average daily volume of 62,608,598 shares. The stock had previously closed at GBX 0.06 ($0.00).

Nuformix Trading Down 12.7 %

The company’s 50-day moving average is GBX 0.05 and its 200 day moving average is GBX 0.10. The company has a market cap of £450,620.50, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.